2 results match your criteria: "Vita-Salute San Raffaele University and Institute for Research and Care[Affiliation]"
Effectiveness and safety of bimekizumab for the treatment of plaque psoriasis: a real-life multicenter study-IL PSO (Italian landscape psoriasis).
Front Med (Lausanne)
August 2023
Dermatology Unit, IRCCS Humanitas Research Hospital, Milan, Italy.
Article Synopsis
- Bimekizumab, a monoclonal antibody targeting Interleukin-17 A and F, is effective for moderate-to-severe plaque psoriasis, though real-world data is limited.
- A retrospective study in 19 Italian hospitals assessed 237 patients treated with bimekizumab, measuring psoriasis severity at 4 and 16 weeks based on PASI scores.
- Results showed significant improvements in skin clearance and quality of life, with 75.4% achieving clear skin by week 16, and side effects were minimal and manageable.
Melanonychia induced by venlafaxine hydrochloride.
G Ital Dermatol Venereol
August 2019
Unit of Dermatology and Cosmetology, Vita-Salute San Raffaele University and Institute for Research and Care, Milan, Italy.